EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma



Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma



Anticancer Research 25(4): 2761-2765



Interleukin (IL)-6 plays a central role as a differentiation and growth factor of tumor cells. IL-6 has been identified in a wide variety of malignancies, including head and neck squamous cell carcinomas (HNSCC). The aim of this study was to investigate the association between the serum levels of IL-6 in HNSCC patients and the biological characteristics of the tumor as well as the clinicopathological status of the patients.

(PDF emailed within 1 workday: $29.90)

Accession: 012549849

Download citation: RISBibTeXText

PMID: 16080523



Related references

Serum levels of interleukin-7 and interleukin-8 in head and neck squamous cell carcinoma. Indian Journal of Cancer 51(3): 227-230, 2014

Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. Iranian Journal of Otorhinolaryngology 25(72): 161-168, 2013

Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Research 20(5a): 3045-3049, 2000

Serum nitric oxide levels in patients with head and neck squamous cell carcinoma. Kulak Burun Bogaz Ihtisas Dergisi 17(3): 148-151, 2007

Elevated serum levels of malondialdehyde in patients with squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 94, 1994

Health behaviors predict higher interleukin-6 levels among patients newly diagnosed with head and neck squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention 22(3): 374-381, 2013

Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. Journal of Biological Response Modifiers 8(6): 571-578, 1989

High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. International Journal of Cancer 122(4): 857-863, 2007

Tissue expression, serum and salivary levels of IL-10 in patients with head and neck squamous cell carcinoma. Asian Pacific Journal of Cancer Prevention 14(3): 1681-1685, 2014

The serum small cell carcinoma antigen levels in patients with head and neck squamous cell carcinomas. Otologia Fukuoka 32(5): 744-748, 1986

Serum PGE2 levels are inversely correlated with T classification in patients with squamous cell carcinoma of the head and neck. Head & Neck 30(1): 132-3; Author Reply 133, 2007

Melanoma differentiation-associated gene-7/interleukin-24 as a potential prognostic biomarker and second primary malignancy indicator in head and neck squamous cell carcinoma patients. Tumour Biology 35(11): 10977-10985, 2015

Evaluation of serum levels of oxidized and reduced glutathione and total antioxidant capacity in patients with head and neck squamous cell carcinoma. Journal of Cancer Research and Therapeutics 14(2): 428-431, 2018

Tu1625 Clinical Impact of Screening for Head and Neck Region and Intervention for Early Head and Neck Squamous Cell Carcinoma in Patients With Esophageal Squamous Cell Carcinoma. Gastrointestinal Endoscopy 75(4): Ab468-Ab469, 2012

Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clinical Cancer Research 11(5): 1899-1909, 2005